US20030049295A1 - Process for preparing antimicrobial plastic bodies having improved long-time performance - Google Patents
Process for preparing antimicrobial plastic bodies having improved long-time performance Download PDFInfo
- Publication number
- US20030049295A1 US20030049295A1 US10/060,835 US6083502A US2003049295A1 US 20030049295 A1 US20030049295 A1 US 20030049295A1 US 6083502 A US6083502 A US 6083502A US 2003049295 A1 US2003049295 A1 US 2003049295A1
- Authority
- US
- United States
- Prior art keywords
- precursor
- treated
- silver
- inorganic particles
- plastic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L75/00—Compositions of polyureas or polyurethanes; Compositions of derivatives of such polymers
- C08L75/04—Polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L29/126—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/20—Compounding polymers with additives, e.g. colouring
- C08J3/205—Compounding polymers with additives, e.g. colouring in the presence of a continuous liquid phase
- C08J3/2053—Compounding polymers with additives, e.g. colouring in the presence of a continuous liquid phase the additives only being premixed with a liquid phase
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/04—Coating
- C08J7/043—Improving the adhesiveness of the coatings per se, e.g. forming primers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/04—Coating
- C08J7/06—Coating with compositions not containing macromolecular substances
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/02—Elements
- C08K3/08—Metals
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K9/00—Use of pretreated ingredients
- C08K9/12—Adsorbed ingredients, e.g. ingredients on carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M2025/0056—Catheters; Hollow probes characterised by structural features provided with an antibacterial agent, e.g. by coating, residing in the polymer matrix or releasing an agent out of a reservoir
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2375/00—Characterised by the use of polyureas or polyurethanes; Derivatives of such polymers
- C08J2375/04—Polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/02—Elements
- C08K3/08—Metals
- C08K2003/0806—Silver
Definitions
- the invention relates to processes for preparing antimicrobial metal-containing plastic bodies, in particular articles for medical requirements. These articles are in particular used in the form of catheters.
- plastic articles for medical requirements in particular of catheters for long-term and short-term use, are easily infected by germs which are often multi-resistant and form a biofilm on the surface of the plastic body or on the outer and interior surface of the catheter. Prophylactic impregnation of the surfaces by means of antibiotics has to be ruled out due to the high selection of resistant microorganisms involved.
- silver ions originating from, e.g., silver nitrate, acetate or chloride.
- silver ions have a very broad antimicrobial spectrum and high toxicity towards microorganisms in that they, e.g., bind to the cell wall via SH groups, block the respiratory chain, stop cell proliferation via DNA binding, but have low toxicity towards animal cells.
- sufficient microbial activity could not be observed in various clinical studies.
- the etching effect and the poor water solubility, respectively, of silver salts cause further problems in use.
- metal ions silver ions
- Admixing a polymer such as polyurethane with a metal powder such as silver powder will not be successful since due to the small surface area relatively high concentrations of metal powder will be necessary, which causes mechanical problems in the plastic material.
- the critical surface area required for antimicrobial activity thus, cannot be obtained by admixing metal powder.
- EP-A-0 711 113 discloses a new technology in which metallic silver is vapor deposited on polyurethane films which are compounded in comminuted form. This made it possible to achieve uniform distribution of silver particles in polymer material and, thus, obtain a surface area sufficiently large for bacteriostatic activity.
- the antimicrobial activity of said plastic bodies has been very well established as regards reduction and prevention of adherence, biofilm formation and long-time performance as well as toxicity and compatibility.
- the applicability of the aforesaid plastic bodies is, however, limited due to the time-consuming and costly preparation process, in particular caused by the vapor deposition of silver.
- U.S. Pat. No. 5,180,585 furthermore describes an antimicrobial composition comprising inorganic particles having a first microbicidal layer and a second layer which protects the underlying first layer.
- the preparation process is relatively complex.
- the object underlying the present invention is to provide a process for preparing antimicrobially active plastic bodies which do not exhibit the aforesaid disadvantages, i.e. can easily be prepared and provide sufficient concentration of silver ions at the surface.
- polymer compounds commonly used in the medical field can be used as the starting material for the plastic body.
- these are in particular polyethylene, polypropylene, crosslinked polysiloxanes, polyurethanes, (meth)acrylate-based polymers, cellulose and cellulose derivatives, polycarbonates, ABS, tetrafluoroethylene polymers, and polyethylene terephthalates as well as the corresponding copolymers.
- Polyurethane, polyethylene and polypropylene as well as polyethylene-polypropylene copolymers are particularly preferred.
- the metal used is preferably silver, copper, gold, zinc or cerium. Among these metals, silver is particularly preferred.
- colloidal metal Apart from colloidal metal, one or several polymer materials are used in the preparation of the plastic bodies according to the invention. Further additives can also be added to the mixture of colloidal metal and plastic(s). These are, in particular, inorganic particles such as barium sulfate, calcium sulfate, strontium sulfate, titanium oxide, aluminium oxide, silicon oxide, zeolites, mica, talcum, kaolin etc. In this context, barium sulfate which can simultaneously act as a X-ray contrast medium for specific fields of application is particularly preferred.
- inorganic particles such as barium sulfate, calcium sulfate, strontium sulfate, titanium oxide, aluminium oxide, silicon oxide, zeolites, mica, talcum, kaolin etc.
- barium sulfate which can simultaneously act as a X-ray contrast medium for specific fields of application is particularly preferred.
- the resulting mixture is further processed in order to obtain a molded plastic article. This can be done in mixers, kneaders, extruders, injection molding machines or (hot) presses.
- the metal colloids with which the plastic materials or inorganic particles are treated are suitably prepared by reducing metal salt solutions.
- protective agents such as gelatin, silica or starch may be used.
- a preferred metal silver colloid is prepared by slowly blending an ammoniacal silver nitrate solution in gelatin with a suitable reducing agent.
- the reducing agent preferably is selected from aldehydes (e.g. acetaldehyde), aldoses (e.g. glucose), quinones (e.g. hydroquinone), inorganic complex hydrides (sodium or potassium boranate), reducing nitrogen compounds (hydrazine, polyethylene imine) and ascorbic acid.
- Plastic precursors such as pellets and/or said inorganic particles such as barium sulfate are then treated with said colloidal silver solution, dried and molded into the respective shape. Applying said silver colloid onto the starting materials and subsequent drying can be repeated several times so that in this way very high silver concentrations can be introduced into the plastic material. This is of particular advantage if barium sulfate is coated with silver since in this way the plastic pellets do not necessarily have to be coated in advance.
- the suspension can also be freed from solvent by filtration and it can subsequently be freed from all low-molecular organic compounds by first washing it with about 5% ammonia solution and then several times with distilled water. As described above, after drying in air the filter residue will give a homogeneous material. This process can also be repeated several times.
- the particle size of the silver and, thus, the mobility of the resulting silver ions can be controlled over a wide range and, moreover, by using low-molecular aldehydes as the reducing agents which partially crosslink gelatin, very strong adhesion to the polymer can be achieved.
- 1.0 g gelatin (DAB) are dissolved in 100 ml distilled water at 40° C. whilst stirring. Subsequently, 1.0 g (5.88 mmol) AgNO 3 p.a. are added thereto and the resulting solution is blended with 1.0 ml (14.71 mmol) water containing 25% NH 3 .
- the silver colloid is separated by rapid filtration over a folded filter of a suitable pore size, the pellets are once again washed with the filtrate and the still wet pellets are transferred into a evaporating dish. After superfluous silver colloid solution which does not adhere to the polymer has been removed, the resulting product is dried for 10 h at 70° C.
- a solution of 3.53 g anhydrous ⁇ -D-glucose in 150 ml distilled water is slowly dripped in at 50° C. whilst stirring vigorously and as soon as about half of the glucose solution has been dripped in, the resultant silver colloid is blended with 333 g BaSO 4 . After the dripping has been stopped, the suspension is further turbinated for about 2 h at 50° C. and then freed from its volatile components by evaporation and drying at 70° C. The material is comminuted in a hand-held mortar.
- Example 3a The procedure is analogous to Example 3a), with the exception that 1.2 l distilled water, 2 g gelatin, 20 g AgNO 3 and 26 ml 25% NH 3 solution are used.
- As the reducing agent a solution of 10.59 g glucose in 400 ml distilled water is used and blended with 333 g BaSO 4 in analogy with Example 3a). The suspension is then further turbinated for 3 h at 50° C. and kept for about 8 h at 70° C. until the reaction is complete.
- the Ag-colloid adsorbed on BaSO 4 is freed from water and the components soluble therein (gelatin, gluconic acid, NH 4 NO 3 and NH 3 ) by filtering the suspension which still should be as warm as possible and subsequently washing the residue four times with distilled water. Drying takes place at 70° C. and comminution is effected as in Example 3a).
- the residual amount of organic material (gelatin, gluconic acid, glucose) of the material obtained according to Example 4 was determined by means of two independent methods with the proviso that under the conditions used gelatin and gluconic acid have comparable solubility in water.
- the C and H values are below the measuring tolerance indicated by the manufacturer of the apparatus of 0.3%, i.e. with a finished compounded polyurethane material comprising 20% BaSO 4 and 0.8% Ag, the total amount of organic residues can be calculated to be theoretically at most 0.182 wt % (lowest value that can be detected by the apparatus). Thus, the actual value should be considerably lower.
- plastic bodies according to the invention In order to determine whether the plastic bodies according to the invention can be infected with germs, five cylindrical samples each of the respective plastic (diameter 3 mm, length 13 mm) were incubated with a composition containing Staphylococcus epidermis in a Trypcase-Soy-Broth nutrient solution at 175° C. The following plastic bodies were examined (no. 1 is commercially available and untreated, nos. 2 and 3 are according to the invention):
- Specimen 1 section taken from a PU catheter obtained from the company Arrow (ES 04701)
- Test sequence 1 initial concentration of Staphylococcus epidermis 5 ⁇ 10 7 CFU/ml
- Test sequence 2 initial concentration of Staphylococcus epidermis 108 CFU/ml
- Test sequence 3 as in test sequence 1, but measured in physiological buffer solution at 37° C. after previous incubation for 5 hours.
- Test sequence 4 as in test sequence 1, the plastic bodies having been treated with natural urine filtered to be sterile at 37° C. for 4 hours.
- Table 1 shows the number of infected plastic bodies which was determined by visual control. TABLE 1 Number of infected specimens Test Test Test Specimen Sequence Sequence Sequence Sequence Type 1 2 3 4 Comparison 1 3 5 4 5 Invention 2 0 0 0 0 3 0 3 0 0
- the catheter materials are not impaired in their mechanical properties required for therapeutical purposes (roughness, homogeneity and elasticity).
- the process can easily be adapted to varying requirements in the production process, since antimicrobial activity is maintained irrespective of whether the silver is introduced into the polymer material by coating the polyurethane pellets (Example 2) or via the X-ray contrast medium (Examples 3 and 4).
- plastic articles according to the invention show significantly higher antimicrobial activity with respect to adherence and biofilm formation as well as considerably improved long-time performance as compared with prior art materials at comparably lower toxicity.
- Example 4 additionally provides a process for removing all “adjuvant chemicals” from the inorganic contrast medium so that the grant of a protective certificate on the process should be possible.
- Sterilization Storage in a hot-air cabinet at 90° C. for 3 hours. Previous tests showed that after this period of time the samples are free of germs. (even before that time samples are largely not infected with germs)
- Germs S. epidermidis (ref.: Infection Suppl. 6/99)
- samples are incubated with 5 ⁇ 10 7 germs at room temperature in a suspension of 0.45% NaCl with 2.5% glucose for 8 hours
- the germ suspension is subsequently removed by centrifugation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention relates to processes for preparing an antimicrobial plastic body, said processes comprising molding a precursor and being characterized in that prior to molding at least one component of the precursor is treated with a metal colloid.
Description
- The invention relates to processes for preparing antimicrobial metal-containing plastic bodies, in particular articles for medical requirements. These articles are in particular used in the form of catheters.
- A considerable disadvantage of plastic articles for medical requirements, in particular of catheters for long-term and short-term use, is that the plastics used are easily infected by germs which are often multi-resistant and form a biofilm on the surface of the plastic body or on the outer and interior surface of the catheter. Prophylactic impregnation of the surfaces by means of antibiotics has to be ruled out due to the high selection of resistant microorganisms involved.
- Thus, in the past years numerous attempts have been made to impregnate the plastic surfaces with silver ions originating from, e.g., silver nitrate, acetate or chloride. Among all heavy metal ions, silver ions have a very broad antimicrobial spectrum and high toxicity towards microorganisms in that they, e.g., bind to the cell wall via SH groups, block the respiratory chain, stop cell proliferation via DNA binding, but have low toxicity towards animal cells. In this context, however, sufficient microbial activity could not be observed in various clinical studies. Moreover, the etching effect and the poor water solubility, respectively, of silver salts cause further problems in use.
- When metal surfaces such as silver are contacted with physiological NaCl solution, metal ions (silver ions) will be released depending on the size of the metal surface. Admixing a polymer such as polyurethane with a metal powder such as silver powder, however, will not be successful since due to the small surface area relatively high concentrations of metal powder will be necessary, which causes mechanical problems in the plastic material. The critical surface area required for antimicrobial activity, thus, cannot be obtained by admixing metal powder.
- EP-A-0 711 113 discloses a new technology in which metallic silver is vapor deposited on polyurethane films which are compounded in comminuted form. This made it possible to achieve uniform distribution of silver particles in polymer material and, thus, obtain a surface area sufficiently large for bacteriostatic activity. The antimicrobial activity of said plastic bodies has been very well established as regards reduction and prevention of adherence, biofilm formation and long-time performance as well as toxicity and compatibility. The applicability of the aforesaid plastic bodies is, however, limited due to the time-consuming and costly preparation process, in particular caused by the vapor deposition of silver.
- U.S. Pat. No. 5,180,585 furthermore describes an antimicrobial composition comprising inorganic particles having a first microbicidal layer and a second layer which protects the underlying first layer. The preparation process is relatively complex.
- Thus, the object underlying the present invention is to provide a process for preparing antimicrobially active plastic bodies which do not exhibit the aforesaid disadvantages, i.e. can easily be prepared and provide sufficient concentration of silver ions at the surface.
- This problem is solved by means of a process which is characterized in that prior to molding the plastic body at least one component of the precursor of the molded article is treated with a silver colloid.
- Many polymer compounds commonly used in the medical field can be used as the starting material for the plastic body. Among these are in particular polyethylene, polypropylene, crosslinked polysiloxanes, polyurethanes, (meth)acrylate-based polymers, cellulose and cellulose derivatives, polycarbonates, ABS, tetrafluoroethylene polymers, and polyethylene terephthalates as well as the corresponding copolymers. Polyurethane, polyethylene and polypropylene as well as polyethylene-polypropylene copolymers are particularly preferred. The metal used is preferably silver, copper, gold, zinc or cerium. Among these metals, silver is particularly preferred.
- Apart from colloidal metal, one or several polymer materials are used in the preparation of the plastic bodies according to the invention. Further additives can also be added to the mixture of colloidal metal and plastic(s). These are, in particular, inorganic particles such as barium sulfate, calcium sulfate, strontium sulfate, titanium oxide, aluminium oxide, silicon oxide, zeolites, mica, talcum, kaolin etc. In this context, barium sulfate which can simultaneously act as a X-ray contrast medium for specific fields of application is particularly preferred.
- Prior to molding, one or several polymer components and/or one or several of the inorganic additives are treated with the colloidal metal solution.
- After mixing of the starting materials which have (in part) been treated with a colloidal metal, the resulting mixture is further processed in order to obtain a molded plastic article. This can be done in mixers, kneaders, extruders, injection molding machines or (hot) presses.
- The metal colloids with which the plastic materials or inorganic particles are treated are suitably prepared by reducing metal salt solutions. In order to stabilize the resulting colloid, protective agents such as gelatin, silica or starch may be used.
- In one embodiment of the present invention, a preferred metal silver colloid is prepared by slowly blending an ammoniacal silver nitrate solution in gelatin with a suitable reducing agent. The reducing agent preferably is selected from aldehydes (e.g. acetaldehyde), aldoses (e.g. glucose), quinones (e.g. hydroquinone), inorganic complex hydrides (sodium or potassium boranate), reducing nitrogen compounds (hydrazine, polyethylene imine) and ascorbic acid.
- Plastic precursors such as pellets and/or said inorganic particles such as barium sulfate are then treated with said colloidal silver solution, dried and molded into the respective shape. Applying said silver colloid onto the starting materials and subsequent drying can be repeated several times so that in this way very high silver concentrations can be introduced into the plastic material. This is of particular advantage if barium sulfate is coated with silver since in this way the plastic pellets do not necessarily have to be coated in advance.
- The suspension can also be freed from solvent by filtration and it can subsequently be freed from all low-molecular organic compounds by first washing it with about 5% ammonia solution and then several times with distilled water. As described above, after drying in air the filter residue will give a homogeneous material. This process can also be repeated several times.
- The use of e.g. gelatin, (fumed) silica or starch as a colloidal stabilizer can be omitted if silver is adsorbed by the inorganic particles, since the microcrystalline silver particles produced during reduction bind to the surface of said inorganic particles via adsorption and, thus, the formation of a continuous silver coating on the solid is avoided. Water soluble adjuvant chemicals used can be removed with water.
- By varying or omitting the colloidal stabilizers as well as the reducing agents, the particle size of the silver and, thus, the mobility of the resulting silver ions can be controlled over a wide range and, moreover, by using low-molecular aldehydes as the reducing agents which partially crosslink gelatin, very strong adhesion to the polymer can be achieved.
- In the following, the process according to the invention will be exemplified by way of examples.
- 1.0 g gelatin (DAB) are dissolved in 100 ml distilled water at 40° C. whilst stirring. Subsequently, 1.0 g (5.88 mmol) AgNO3 p.a. are added thereto and the resulting solution is blended with 1.0 ml (14.71 mmol) water containing 25% NH3.
- For the preparation of the silver colloid, 258.7 mg (5.88 mmol, 330 μl ) acetaldehyde, dissolved in 50 ml distilled water, are slowly dripped into the above solution at 40° C. over a period of time of 30 min.
- 10 min after the dripping according to Example 1 has been stopped, about 50 mg polyurethane pellets made of Tecothane TT-1085A are added and first vigorously stirred for 2 h at 40° C. and then for 3 h at room temperature so that they are coated with colloidal silver.
- The silver colloid is separated by rapid filtration over a folded filter of a suitable pore size, the pellets are once again washed with the filtrate and the still wet pellets are transferred into a evaporating dish. After superfluous silver colloid solution which does not adhere to the polymer has been removed, the resulting product is dried for 10 h at 70° C.
- a) 0.666 g gelatin and then 6.66 g AgNO3 are subsequently dissolved in 500 ml distilled water at 50° C. About 8.5 ml 25% aqueous NH3 solution are added until the reaction is slightly alkaline.
- A solution of 3.53 g anhydrous α-D-glucose in 150 ml distilled water is slowly dripped in at 50° C. whilst stirring vigorously and as soon as about half of the glucose solution has been dripped in, the resultant silver colloid is blended with 333 g BaSO4. After the dripping has been stopped, the suspension is further turbinated for about 2 h at 50° C. and then freed from its volatile components by evaporation and drying at 70° C. The material is comminuted in a hand-held mortar.
- b) The procedure is analogous to Example 3a), with the exception that 6.66 g fumed silica (Degussa, Aerosil 200) are used instead of gelatin. The particle size of the colloidal silver was in the range of from 10 to 50 nm, as determined via a scanning electron micrograph.
- The procedure is analogous to Example 3a), with the exception that 1.2 l distilled water, 2 g gelatin, 20 g AgNO3 and 26 ml 25% NH3 solution are used. As the reducing agent, a solution of 10.59 g glucose in 400 ml distilled water is used and blended with 333 g BaSO4 in analogy with Example 3a). The suspension is then further turbinated for 3 h at 50° C. and kept for about 8 h at 70° C. until the reaction is complete. The Ag-colloid adsorbed on BaSO4 is freed from water and the components soluble therein (gelatin, gluconic acid, NH4NO3 and NH3) by filtering the suspension which still should be as warm as possible and subsequently washing the residue four times with distilled water. Drying takes place at 70° C. and comminution is effected as in Example 3a).
- The residual amount of organic material (gelatin, gluconic acid, glucose) of the material obtained according to Example 4 was determined by means of two independent methods with the proviso that under the conditions used gelatin and gluconic acid have comparable solubility in water.
- By Combustion Analysis
- In this context the C and H values are below the measuring tolerance indicated by the manufacturer of the apparatus of 0.3%, i.e. with a finished compounded polyurethane material comprising 20% BaSO4 and 0.8% Ag, the total amount of organic residues can be calculated to be theoretically at most 0.182 wt % (lowest value that can be detected by the apparatus). Thus, the actual value should be considerably lower.
- By Thermogravimetry
- When comparing the material obtained according to Example 4 with a reference sample prepared in an identical way, but not washed (weight loss about 3.2%) and pure BaSO4, a total weight loss of at most 0.28 wt % (gelatin: 0.045 wt %, gluconic acid: 0.235 wt %) or better can be observed. Thus, the finished compounded polyurethane comprising 20% BaSO4 and 0.8% Ag exhibits a total content of organic residues of ≦0.056 wt % (gelatin: ≦0.009 wt %, gluconic acid: ≦0,047 wt %). Due to its considerably higher sensitivity, thermogravimetry is preferable over combustion analysis.
- In order to determine whether the plastic bodies according to the invention can be infected with germs, five cylindrical samples each of the respective plastic (diameter 3 mm, length 13 mm) were incubated with a composition containing Staphylococcus epidermis in a Trypcase-Soy-Broth nutrient solution at 175° C. The following plastic bodies were examined (no. 1 is commercially available and untreated, nos. 2 and 3 are according to the invention):
- Specimen 1: section taken from a PU catheter obtained from the company Arrow (ES 04701)
- Specimen 2: according to Example 2 of the present invention
- Specimen 3: according to Example 3 of the present invention.
- The 5 specimens were each subjected to four test sequences under the following conditions:
- Test sequence 1: initial concentration of Staphylococcus epidermis 5×107 CFU/ml
- Test sequence 2: initial concentration of Staphylococcus epidermis 108 CFU/ml Test sequence 3: as in test sequence 1, but measured in physiological buffer solution at 37° C. after previous incubation for 5 hours.
- Test sequence 4: as in test sequence 1, the plastic bodies having been treated with natural urine filtered to be sterile at 37° C. for 4 hours.
- Table 1 shows the number of infected plastic bodies which was determined by visual control.
TABLE 1 Number of infected specimens Test Test Test Test Specimen Sequence Sequence Sequence Sequence Type 1 2 3 4 Comparison 1 3 5 4 5 Invention 2 0 0 0 0 3 0 3 0 0 - After compounding, the catheter materials are not impaired in their mechanical properties required for therapeutical purposes (roughness, homogeneity and elasticity). The process can easily be adapted to varying requirements in the production process, since antimicrobial activity is maintained irrespective of whether the silver is introduced into the polymer material by coating the polyurethane pellets (Example 2) or via the X-ray contrast medium (Examples 3 and 4).
- The plastic articles according to the invention show significantly higher antimicrobial activity with respect to adherence and biofilm formation as well as considerably improved long-time performance as compared with prior art materials at comparably lower toxicity.
- The preparation processes according to the invention can easily be controlled, are economical and suited for large scale production. Example 4 additionally provides a process for removing all “adjuvant chemicals” from the inorganic contrast medium so that the grant of a protective certificate on the process should be possible.
- Catheters (The Amounts are Based on the Finished Compounded Material)
- 1) polyurethane catheters 20% BaSO4+0.8% Ag, length 1.0 cm (Example 4)
- 2a) silicone catheters 25% BaSO4+1% Ag, length 1 cm, thickness 1.3 mm and width 2 mm (Example 4)
- 2b) silicone catheters 25% BaSO4+0.33% Ag+0.33% SiO2 (Example 3b) silicone wall sections, length 1 cm, thickness 1 mm and width 2 mm
- 3) control Argen Tec 1 lumen catheter (Sicuris) Extr. 1/99 20% BaSO4+0.9-1% Ag
- Sterilization: Storage in a hot-air cabinet at 90° C. for 3 hours. Previous tests showed that after this period of time the samples are free of germs. (even before that time samples are largely not infected with germs)
-
-
-
-
- samples are incubated with 5×107 germs at room temperature in a suspension of 0.45% NaCl with 2.5% glucose for 8 hours
- the germ suspension is subsequently removed by centrifugation
- washing two times (2 min of renewed suspension in physiological sodium chloride solution whilst swiveling)
- transferring the samples into sterile sodium chloride solution in a Petri dish
- sampling every hour, after 6 hours every 2 hours and transferring the samples into Trypcase Soja Medium after slight swiveling in physiological sodium chloride solution
- incubation for 24 to 36 hours
- evaluation of the sample for sterility (turbidity=measurement of the end point).
- Results of Tests withS. epidermidis
- All samples are tested five times (+++++)
Results of tests with S. epodermidis All samples are tested five times (+++++) Time: H Sample 1 Sample 2a Sample 2b Control 0 +++++ +++++ +++++ +++++ 1 +++++ +++++ +++++ +++++ 2 +++++ +++++ +++++ +++++ 3 ++++− ++++− +++++ +++++ 4 ++++− ++++− +++++ +++++ 5 ++−−− ++−−− ++++− +++++ 6 −−−−− +−−−− ++−−− +++++ 8 −−−−− −−−−− −−−−− +++++ 10 −−−−− −−−−− −−−−− +++++ 12 −−−−− −−−−− −−−−− ++++− 16 −−−−− −−−−− −−−−− +++−− 18 −−−−− −−−−− −−−−− +++−− - Discussion
- In this test the antimicrobial activity of solids depending on time could be examined. It is shown that silver-filled samples exhibit antimicrobial activity already after 6 hours and a contaminated catheter can be made sterile again within this period of time even at a unphysiologically high inoculum. Lower Ag concentration as in sample 2b will also have a positive result.
Results of tests with E. coli All samples are tested five times (+++++) Time: H Sample 1 Sample 2a Sample 2b Control 0 +++++ +++++ +++++ 1 +++++ +++++ +++++ 2 +++++ +++++ +++++ 3 ++++− +++++ +++++ 4 ++++− +++++ +++++ 5 ++++− ++++− +++++ 6 +++−− ++++− +++++ 8 ++−−− +++−− +++++ 10 +−−−− +−−−− +++++ 12 −−−−− −−−−− +++++ 16 −−−−− −−−−− ++++− 18 −−−−− −−−−− ++++− - The results forS. epidermidis are equally good even after the silver has been eluted in physiological NaCl solution for 1, 2 and 3 weeks and the results are identical to those in Table 1.
- The examination for cytotoxicity was carried out by the company Toxikon, Bedford Mass., U.S.A. It was shown that the samples prepared are not toxic and fulfil the requirements of the elution test ISO 10993.
Claims (15)
1. A process for preparing an antimicrobial plastic body, said process comprising molding a precursor and being characterized in that prior to molding at least one component of the precursor is treated with a metal colloid.
2. The process as claimed in claim 1 wherein the precursor consists of one or several polymer materials.
3. The process as claimed in claim 2 wherein said precursor consists of polyurethane.
4. The process as claimed in any one of claims 1 to 3 wherein apart from polymeric materials further additives are added to the plastic precursor.
5. The process as claimed in claim 4 wherein said additives consist of inorganic particles.
6. The process as claimed in claim 5 wherein said inorganic particles comprise barium sulfate, calcium sulfate, strontium sulfate, titanium oxide, aluminium oxide, silicon oxide, zeolites, mica, talcum or kaolin.
7. The process as claimed in claim 6 wherein said inorganic particles comprise barium sulfate and/or fumed silica.
8. The process as claimed in any one of claims 1 to 7 wherein one or several of the components of the precursor are treated with said colloidal metal.
9. The process as claimed in any one of claims 4 to 7 wherein said plastic as well as said inorganic particles are treated with said colloidal metal.
10. The process as claimed in any one of claims 4 to 7 wherein said inorganic particles are treated with said metal colloid.
11. The process as claimed in any one of claims 1 to 10 wherein said metal colloid is colloidal silver.
12. The process as claimed in any one of claims 1 to 11 wherein said treated precursor is given its final shape by mixing, kneading, extruding, injection molding or (hot) press molding.
13. A plastic body obtainable according to any one of claims 1 to 12 .
14. The plastic body as claimed in claim 13 wherein said colloidal silver has a particle size of from 10 to 50 nm.
15. The plastic body as claimed in claim 13 or 14 in the form of a catheter.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/789,232 US8075823B2 (en) | 1999-07-30 | 2007-04-24 | Process for preparing antimicrobial plastic bodies having improved long-time performance |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19936059.6 | 1999-07-30 | ||
DE19936059A DE19936059A1 (en) | 1999-07-30 | 1999-07-30 | Production of antimicrobial plastic articles, especially catheters, involves pretreatment with colloidal metal, especially colloidal silver, before the final moulding process |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/789,232 Continuation US8075823B2 (en) | 1999-07-30 | 2007-04-24 | Process for preparing antimicrobial plastic bodies having improved long-time performance |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030049295A1 true US20030049295A1 (en) | 2003-03-13 |
Family
ID=7916729
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/060,835 Abandoned US20030049295A1 (en) | 1999-07-30 | 2002-01-30 | Process for preparing antimicrobial plastic bodies having improved long-time performance |
US11/789,232 Expired - Fee Related US8075823B2 (en) | 1999-07-30 | 2007-04-24 | Process for preparing antimicrobial plastic bodies having improved long-time performance |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/789,232 Expired - Fee Related US8075823B2 (en) | 1999-07-30 | 2007-04-24 | Process for preparing antimicrobial plastic bodies having improved long-time performance |
Country Status (2)
Country | Link |
---|---|
US (2) | US20030049295A1 (en) |
DE (1) | DE19936059A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040161445A1 (en) * | 2002-05-02 | 2004-08-19 | As Audio Service Gmbh | Hearing aid or hearing aid components for placement in the auditory canal and/or the auricle of a wearer |
US20040239004A1 (en) * | 2003-05-31 | 2004-12-02 | Kim Jin Soo | Method for producing an injection-molded material with an antibacterial function |
US20050246849A1 (en) * | 2004-05-10 | 2005-11-10 | Minkler Douglas J | Sanitizing handle for cleaning tool |
US20060034423A1 (en) * | 1998-08-07 | 2006-02-16 | Juergen Pensel | Surgical microscope |
US20060134313A1 (en) * | 2002-09-10 | 2006-06-22 | Josef-Peter Guggenbichler | Methods for producing an anti-microbial plastic product |
US20070142533A1 (en) * | 2005-12-15 | 2007-06-21 | Gil Sun Ok | Nano-silver infused polymeric composition and methods of manufacturing the same |
US20080268011A1 (en) * | 2004-09-24 | 2008-10-30 | Helmut Goldmann | Antimicrobial Implant with a Flexible Porous Structure |
US20090252804A1 (en) * | 2008-04-08 | 2009-10-08 | Bayer Materialscience Ag | Medical devices with an antibacterial polyurethaneurea coating |
US20090252699A1 (en) * | 2008-04-08 | 2009-10-08 | Bayer Materialscience Ag | Medical devices with an antimicrobial polyurethane coating |
US20090253848A1 (en) * | 2008-04-08 | 2009-10-08 | Bayer Materialscience Ag | Aqueous silver-containing nonionic polyurethane dispersions |
US7935141B2 (en) | 2005-08-17 | 2011-05-03 | C. R. Bard, Inc. | Variable speed stent delivery system |
US8062344B2 (en) | 2001-04-30 | 2011-11-22 | Angiomed Gmbh & Co. Medizintechnik Kg | Variable speed self-expanding stent delivery system and luer locking connector |
US8500789B2 (en) | 2007-07-11 | 2013-08-06 | C. R. Bard, Inc. | Device for catheter sheath retraction |
US20140099350A1 (en) * | 2006-02-17 | 2014-04-10 | Dynamic Adsorbents, Inc. | Anti-biocontaminant Products and Processes for Making the Same |
US8808346B2 (en) | 2006-01-13 | 2014-08-19 | C. R. Bard, Inc. | Stent delivery system |
US9078779B2 (en) | 2006-08-07 | 2015-07-14 | C. R. Bard, Inc. | Hand-held actuator device |
US9801745B2 (en) | 2010-10-21 | 2017-10-31 | C.R. Bard, Inc. | System to deliver a bodily implant |
US11026822B2 (en) | 2006-01-13 | 2021-06-08 | C. R. Bard, Inc. | Stent delivery system |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19936059A1 (en) | 1999-07-30 | 2001-02-01 | J Peter Guggenbichler | Production of antimicrobial plastic articles, especially catheters, involves pretreatment with colloidal metal, especially colloidal silver, before the final moulding process |
DE10120802A1 (en) * | 2001-04-27 | 2002-10-31 | Basf Ag | Process for the production of coated nanoparticles |
GB0110551D0 (en) | 2001-04-30 | 2001-06-20 | Angiomed Ag | Self-expanding stent delivery service |
WO2003003944A2 (en) | 2001-07-06 | 2003-01-16 | Angiomed Gmbh & Co. Medizintechnik Kg | Delivery system having a rapid pusher assembly for self-expanding stent, and stent exchange configuration |
GB0123633D0 (en) | 2001-10-02 | 2001-11-21 | Angiomed Ag | Stent delivery system |
US7491768B2 (en) | 2002-06-25 | 2009-02-17 | Woong-Sig Moon | Polymer resin formulation having anti-microbial or anti-coagulability and preparation method thereof |
JP4757187B2 (en) | 2003-01-15 | 2011-08-24 | アンジオメト・ゲーエムベーハー・ウント・コンパニー・メディツィンテクニク・カーゲー | Tube surgery equipment |
DE10323597A1 (en) * | 2003-05-19 | 2004-12-09 | Aesculap Ag & Co. Kg | Medical device, process for its manufacture and use |
DE102007003538A1 (en) * | 2007-01-24 | 2008-07-31 | Raumedic Ag | Method for producing a medical work equipment, medical work equipment produced by such a method and use of such a medical work equipment |
DE102008033224A1 (en) * | 2008-07-15 | 2010-01-21 | Bio-Gate Ag | Process for the preparation of a composite material with antimicrobial action |
DE102010035867A1 (en) | 2010-08-30 | 2012-03-01 | Retec Kunststofftechnik Gmbh | Prosthesis starting material, in particular for dental prostheses |
DE102017121439A1 (en) | 2017-09-15 | 2019-03-21 | Hecosol Gmbh | Anti-microbial coating |
EP3907261A1 (en) | 2020-05-06 | 2021-11-10 | Hecosol GmbH | Use of antimicrobial coating |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2806798A (en) * | 1953-07-08 | 1957-09-17 | Du Pont | Process for preparing yellow colloidal silver |
US4054139A (en) * | 1975-11-20 | 1977-10-18 | Crossley Kent B | Oligodynamic catheter |
US4677143A (en) * | 1984-10-01 | 1987-06-30 | Baxter Travenol Laboratories, Inc. | Antimicrobial compositions |
US5019096A (en) * | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
US5180585A (en) * | 1991-08-09 | 1993-01-19 | E. I. Du Pont De Nemours And Company | Antimicrobial compositions, process for preparing the same and use |
US5236649A (en) * | 1988-12-23 | 1993-08-17 | The Dow Chemical | Extrudable thermoplastic particulates |
US5418056A (en) * | 1989-11-24 | 1995-05-23 | Mitsuboshi Belting Ltd. | Polymer composite with dispersed fine grains and a method for manufacturing the same |
US5476881A (en) * | 1993-02-15 | 1995-12-19 | Suh; Kang I. | Antimicrobial composition for manufacturing nipples |
US5503840A (en) * | 1991-08-09 | 1996-04-02 | E. I. Du Pont De Nemours And Company | Antimicrobial compositions, process for preparing the same and use |
US5516480A (en) * | 1992-08-13 | 1996-05-14 | Peter Guggenbichler | Bactericidal and/or fungicidal plastic parts for use in the medical field |
US5538766A (en) * | 1992-07-06 | 1996-07-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics & Space Administration | Method for retarding oxidation of an organic substrate |
US5662913A (en) * | 1991-04-10 | 1997-09-02 | Capelli; Christopher C. | Antimicrobial compositions useful for medical applications |
US5824267A (en) * | 1994-08-01 | 1998-10-20 | Kawasumi Laboritories, Inc. | Metallic bactericidal agent |
US5837275A (en) * | 1992-05-19 | 1998-11-17 | Westaim Technologies, Inc. | Anti-microbial materials |
US5976562A (en) * | 1994-02-01 | 1999-11-02 | Krall; Theodor | Process for producing bactericidal/fungicidal plastic bodies |
US6720006B2 (en) * | 1999-06-17 | 2004-04-13 | Bernhard Hanke | Anti-microbial body care product |
US20050130163A1 (en) * | 2002-07-12 | 2005-06-16 | Smith William E. | Serrs reactive particles |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2809798A (en) | 1953-05-15 | 1957-10-15 | Kenney Mfg Co | Drapery bracket |
DE2217399A1 (en) | 1972-04-11 | 1973-10-25 | Allor Corp | Antimicrobial compsn - contg colloidal heavy metals |
ATE88324T1 (en) | 1984-12-28 | 1993-05-15 | Johnson Matthey Plc | ANTIMICROBIAL COMPOSITIONS. |
WO1987003495A1 (en) | 1985-12-16 | 1987-06-18 | Denver Surgical Developments, Inc. | Antimicrobial catheter and method |
US4917686A (en) | 1985-12-16 | 1990-04-17 | Colorado Biomedical, Inc. | Antimicrobial device and method |
GB8616294D0 (en) | 1986-07-03 | 1986-08-13 | Johnson Matthey Plc | Antimicrobial compositions |
US4871790A (en) | 1987-11-25 | 1989-10-03 | Minnesota Mining And Manufacturing Company | Colloidal metals in monomers or polymers |
US4851081A (en) * | 1988-06-30 | 1989-07-25 | Celanese Engineering Resins | Process for preparing conductive plastic articles |
DE3837125A1 (en) | 1988-11-02 | 1990-05-03 | Signode System Gmbh | Process for the production of mouldings from metal and a thermoplastic |
JPH02298517A (en) | 1989-01-17 | 1990-12-10 | Sekisui Chem Co Ltd | Production of inorganic antimicrobial agent-containing molded product made of thermoplastic resin |
EP0427858A4 (en) | 1989-02-28 | 1993-03-10 | Kanebo Ltd. | Antibacterial or conductive composition and applications thereof |
JPH0345709A (en) | 1989-07-10 | 1991-02-27 | Nichibi:Kk | Antimicrobial fiber and production thereof |
JPH0686571B2 (en) | 1989-10-06 | 1994-11-02 | 株式会社日板研究所 | Antibacterial / conductive composition and antibacterial / conductive resin composition |
DE3942112A1 (en) | 1989-12-20 | 1991-06-27 | Braun Melsungen Ag | MEDICAL DEVICE WITH AN OLIGODYNAMICALLY ACTIVE MATERIAL |
US5063179A (en) * | 1990-03-02 | 1991-11-05 | Cabot Corporation | Process for making non-porous micron-sized high purity silica |
JPH04231062A (en) | 1990-09-18 | 1992-08-19 | Create Medic Kk | Antimicrobial medical product |
JP3218605B2 (en) | 1990-12-25 | 2001-10-15 | ラサ工業株式会社 | Antibacterial phosphate intercalation compound and method for producing the same |
DE4143239A1 (en) | 1991-12-31 | 1993-07-01 | Joerg Dipl Chem Schierholz | PHARMACEUTICAL ACTIVE SUBSTANCES CONTAINING AN IMPLANTABLE DEVICE FROM A POLYMERIC MATERIAL AND METHOD FOR THE PRODUCTION THEREOF |
US5681575A (en) | 1992-05-19 | 1997-10-28 | Westaim Technologies Inc. | Anti-microbial coating for medical devices |
AU4278593A (en) | 1993-01-15 | 1994-08-15 | E.I. Du Pont De Nemours And Company | Antimicrobial compositions, process for preparing the same and use |
JP3309869B2 (en) | 1993-03-08 | 2002-07-29 | ラサ工業株式会社 | Antibacterial thermoplastic resin composition and antibacterial molded article |
JP2700523B2 (en) | 1993-07-19 | 1998-01-21 | 憲司 中村 | Antibacterial powder and manufacturing method thereof |
JP3624354B2 (en) * | 1993-07-23 | 2005-03-02 | 大日精化工業株式会社 | Method for producing antibacterial resin composition |
JP3003473B2 (en) | 1993-09-28 | 2000-01-31 | ダイソー株式会社 | Antibacterial organic polymer material |
DE4402890A1 (en) | 1994-02-01 | 1995-08-03 | Basf Ag | Process for the production of compositions containing metal particles in the nanometer size range |
JPH07238001A (en) * | 1994-02-28 | 1995-09-12 | Matsushita Electric Ind Co Ltd | Antimicrobial additive for resin and molding of antimicrobial resin |
JP3371582B2 (en) | 1994-11-01 | 2003-01-27 | ジェイエスアール株式会社 | Antibacterial thermoplastic elastomer composition |
DE19640364A1 (en) | 1996-09-30 | 1998-04-02 | Basf Ag | Topical agents for the prophylaxis or treatment of bacterial skin infections |
US6013106A (en) | 1997-01-22 | 2000-01-11 | St. Jude Medical, Inc. | Medical article with adhered antimicrobial metal ions and related methods |
JPH11172154A (en) | 1997-12-08 | 1999-06-29 | Nichiban Kenkyusho:Kk | Composition for antistatic processing |
JPH11169724A (en) | 1997-12-17 | 1999-06-29 | San Techno:Kk | Composite particle material having anti-bacterial function |
DE19756790A1 (en) | 1997-12-19 | 1999-07-01 | Fraunhofer Ges Forschung | Prepolymer with dispersed nanoscale solid particles isolated therein, process for its preparation and its use |
DE19936059A1 (en) | 1999-07-30 | 2001-02-01 | J Peter Guggenbichler | Production of antimicrobial plastic articles, especially catheters, involves pretreatment with colloidal metal, especially colloidal silver, before the final moulding process |
DE10013248A1 (en) | 2000-03-17 | 2001-09-20 | J Peter Guggenbichler | Production of antimicrobial plastic articles, especially catheters, involves pretreatment with colloidal metal, especially colloidal silver, before the final moulding process |
DE50007020D1 (en) | 1999-07-30 | 2004-08-12 | J Peter Guggenbichler | METHOD FOR PRODUCING ANTIMICROBIAL PLASTIC BODIES WITH IMPROVED LONG-TERM BEHAVIOR |
JP4243908B2 (en) | 2000-02-04 | 2009-03-25 | 横浜ゴム株式会社 | Injection mold for golf ball molding |
-
1999
- 1999-07-30 DE DE19936059A patent/DE19936059A1/en not_active Withdrawn
-
2002
- 2002-01-30 US US10/060,835 patent/US20030049295A1/en not_active Abandoned
-
2007
- 2007-04-24 US US11/789,232 patent/US8075823B2/en not_active Expired - Fee Related
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2806798A (en) * | 1953-07-08 | 1957-09-17 | Du Pont | Process for preparing yellow colloidal silver |
US4054139A (en) * | 1975-11-20 | 1977-10-18 | Crossley Kent B | Oligodynamic catheter |
US4677143A (en) * | 1984-10-01 | 1987-06-30 | Baxter Travenol Laboratories, Inc. | Antimicrobial compositions |
US5019096A (en) * | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
US5236649A (en) * | 1988-12-23 | 1993-08-17 | The Dow Chemical | Extrudable thermoplastic particulates |
US5418056A (en) * | 1989-11-24 | 1995-05-23 | Mitsuboshi Belting Ltd. | Polymer composite with dispersed fine grains and a method for manufacturing the same |
US5662913A (en) * | 1991-04-10 | 1997-09-02 | Capelli; Christopher C. | Antimicrobial compositions useful for medical applications |
US5503840A (en) * | 1991-08-09 | 1996-04-02 | E. I. Du Pont De Nemours And Company | Antimicrobial compositions, process for preparing the same and use |
US5180585A (en) * | 1991-08-09 | 1993-01-19 | E. I. Du Pont De Nemours And Company | Antimicrobial compositions, process for preparing the same and use |
US5837275A (en) * | 1992-05-19 | 1998-11-17 | Westaim Technologies, Inc. | Anti-microbial materials |
US5538766A (en) * | 1992-07-06 | 1996-07-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics & Space Administration | Method for retarding oxidation of an organic substrate |
US5516480A (en) * | 1992-08-13 | 1996-05-14 | Peter Guggenbichler | Bactericidal and/or fungicidal plastic parts for use in the medical field |
US5476881A (en) * | 1993-02-15 | 1995-12-19 | Suh; Kang I. | Antimicrobial composition for manufacturing nipples |
US5976562A (en) * | 1994-02-01 | 1999-11-02 | Krall; Theodor | Process for producing bactericidal/fungicidal plastic bodies |
US6544536B1 (en) * | 1994-02-01 | 2003-04-08 | J. Peter Guggenbichler | Bactericidal/fungicidal plastic articles |
US5824267A (en) * | 1994-08-01 | 1998-10-20 | Kawasumi Laboritories, Inc. | Metallic bactericidal agent |
US6720006B2 (en) * | 1999-06-17 | 2004-04-13 | Bernhard Hanke | Anti-microbial body care product |
US6822034B2 (en) * | 1999-06-17 | 2004-11-23 | Bernhard Hanke | Anti-microbial silicone rubber composition and method for making same |
US20050130163A1 (en) * | 2002-07-12 | 2005-06-16 | Smith William E. | Serrs reactive particles |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060034423A1 (en) * | 1998-08-07 | 2006-02-16 | Juergen Pensel | Surgical microscope |
WO2006117757A1 (en) * | 1998-08-07 | 2006-11-09 | Leica Microsystems (Schweiz) Ag | Surgical microscope comprising a surface with bactericidal or fungicidal material intercalated therein |
US8062344B2 (en) | 2001-04-30 | 2011-11-22 | Angiomed Gmbh & Co. Medizintechnik Kg | Variable speed self-expanding stent delivery system and luer locking connector |
US20040161445A1 (en) * | 2002-05-02 | 2004-08-19 | As Audio Service Gmbh | Hearing aid or hearing aid components for placement in the auditory canal and/or the auricle of a wearer |
US20100068296A1 (en) * | 2002-09-10 | 2010-03-18 | Antimicrobial Argentum Technologies | Methods for producing an anti-microbial plastic product |
US20060134313A1 (en) * | 2002-09-10 | 2006-06-22 | Josef-Peter Guggenbichler | Methods for producing an anti-microbial plastic product |
US20040239004A1 (en) * | 2003-05-31 | 2004-12-02 | Kim Jin Soo | Method for producing an injection-molded material with an antibacterial function |
US20050246849A1 (en) * | 2004-05-10 | 2005-11-10 | Minkler Douglas J | Sanitizing handle for cleaning tool |
US20080268011A1 (en) * | 2004-09-24 | 2008-10-30 | Helmut Goldmann | Antimicrobial Implant with a Flexible Porous Structure |
US7935141B2 (en) | 2005-08-17 | 2011-05-03 | C. R. Bard, Inc. | Variable speed stent delivery system |
US20070142533A1 (en) * | 2005-12-15 | 2007-06-21 | Gil Sun Ok | Nano-silver infused polymeric composition and methods of manufacturing the same |
US11026822B2 (en) | 2006-01-13 | 2021-06-08 | C. R. Bard, Inc. | Stent delivery system |
US9675486B2 (en) | 2006-01-13 | 2017-06-13 | C.R. Bard, Inc. | Stent delivery system |
US8808346B2 (en) | 2006-01-13 | 2014-08-19 | C. R. Bard, Inc. | Stent delivery system |
US20140099350A1 (en) * | 2006-02-17 | 2014-04-10 | Dynamic Adsorbents, Inc. | Anti-biocontaminant Products and Processes for Making the Same |
US9078779B2 (en) | 2006-08-07 | 2015-07-14 | C. R. Bard, Inc. | Hand-held actuator device |
US10993822B2 (en) | 2006-08-07 | 2021-05-04 | C. R. Bard, Inc. | Hand-held actuator device |
US8500789B2 (en) | 2007-07-11 | 2013-08-06 | C. R. Bard, Inc. | Device for catheter sheath retraction |
US9421115B2 (en) | 2007-07-11 | 2016-08-23 | C. R. Bard, Inc. | Device for catheter sheath retraction |
US10206800B2 (en) | 2007-07-11 | 2019-02-19 | C.R. Bard, Inc. | Device for catheter sheath retraction |
US11026821B2 (en) | 2007-07-11 | 2021-06-08 | C. R. Bard, Inc. | Device for catheter sheath retraction |
US20090253848A1 (en) * | 2008-04-08 | 2009-10-08 | Bayer Materialscience Ag | Aqueous silver-containing nonionic polyurethane dispersions |
US20090252804A1 (en) * | 2008-04-08 | 2009-10-08 | Bayer Materialscience Ag | Medical devices with an antibacterial polyurethaneurea coating |
US20090252699A1 (en) * | 2008-04-08 | 2009-10-08 | Bayer Materialscience Ag | Medical devices with an antimicrobial polyurethane coating |
US9801745B2 (en) | 2010-10-21 | 2017-10-31 | C.R. Bard, Inc. | System to deliver a bodily implant |
US10952879B2 (en) | 2010-10-21 | 2021-03-23 | C. R. Bard, Inc. | System to deliver a bodily implant |
Also Published As
Publication number | Publication date |
---|---|
DE19936059A1 (en) | 2001-02-01 |
US8075823B2 (en) | 2011-12-13 |
US20070194483A1 (en) | 2007-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8075823B2 (en) | Process for preparing antimicrobial plastic bodies having improved long-time performance | |
JP2014080624A (en) | Process for preparing antimicrobial plastic bodies having improved long-time performance | |
JP5128757B2 (en) | Manufacturing method of antibacterial plastic products | |
US4381380A (en) | Thermoplastic polyurethane article treated with iodine for antibacterial use | |
DK170231B1 (en) | Medical equipment and methods of manufacture thereof | |
US8673441B2 (en) | Antimicrobial plastics product and process for production thereof | |
US7179849B2 (en) | Antimicrobial compositions containing colloids of oligodynamic metals | |
EP1781098B1 (en) | Antimicrobial devices and compositions | |
US7381751B2 (en) | Antimicrobial composition for medical articles | |
US20060045899A1 (en) | Antimicrobial composition for medical articles | |
CA2210119A1 (en) | An antimicrobial medical device and method | |
WO2004017738A1 (en) | Antimicrobial compositions containing colloids of oligodynamic metals | |
RU2416435C1 (en) | Method of antiseptic surface preparation of product made of polymeric material | |
EP2968686A1 (en) | Polymeric coatings having antimicrobial properties | |
JPH04231062A (en) | Antimicrobial medical product | |
JP4339456B2 (en) | Antibacterial paint and antibacterial product using the same | |
Ospanova et al. | Obtaining thin-films based on chitosan and carboxymethylcellulose with antibacterial properties for biomedical devices | |
DE10013248A1 (en) | Production of antimicrobial plastic articles, especially catheters, involves pretreatment with colloidal metal, especially colloidal silver, before the final moulding process | |
EP3445816B1 (en) | Antimicrobially active, non-leaching thermoplastic molding compounds | |
CN116874981A (en) | Polymer nanogel, antimicrobial nanogel containing nanogel, coating and material | |
DUŢĂ et al. | PVC modification by incorporating silver nanoparticles on the surface | |
JP2005290294A (en) | Germicidal resin molded article and method for producing the same | |
Szycher | -Antimicrobial Polyurethanes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |